Vertex Pharmaceuticals' $10 B Acquisition of Crinetics Expands Endocrinology Portfolio

Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, valuing the deal at about $10 billion (approximately $8.8 billion net of cash). The transaction adds two lead endocrine assets: PALSONIFY, the first once‑daily oral therapy for adults with acromegaly, and atumelnant, an investigational ACTH‑receptor antagonist being developed for congenital adrenal hyperplasia (CAH) and ACTH‑dependent Cushing’s syndrome.

Vertex CEO Dr. Reshma Kewalramani highlighted PALSONIFY’s strong market uptake, noting a 40‑50 % share of new‑to‑brand prescriptions in its second quarter and growing payer coverage. Phase‑2 data for atumelnant showed a 67 % reduction in androgen levels and the ability to taper glucocorticoid dosing. Analyst coverage of Crinetics shifted after the announcement, with Wall Street Zen upgrading the stock to a “sell,” while other firms moved ratings to “hold” or adjusted price targets, reflecting mixed sentiment on integration risk and future earnings prospects.